Study: At least 11% of Geneva’s population has antibodies to SARS-CoV2A new study in The Lancet shows that the population prevalence of antibodies to SARS-CoV2, the virus that causes COVID-19, grew in Geneva, Switzerland, in April from 5% to 11%."At what appears to be the tail end of the first wave of the pandemic in Switzerland, about one in ten people have developed detectable antibodies against SARS-CoV-2, despite the fact that it was one of the more heavily affected areas in Europe," the authors of the study said.The findings come from the Swiss SEROCoV-POP study, which will conduct serosurveillance in Geneva for 12 weeks.